Cancer Chemotherapy and Pharmacology

, Volume 63, Issue 6, pp 1161–1163

Isolated molecular relapse in FIP1L1-PDGFRα hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose

Authors

    • Department of Cellular Biotechnology and HematologyUniversity La Sapienza
    • Department of Human Biotechnology and Hematology
  • Daniela Cilloni
    • Department of Clinical and Biological Sciences of the University of TurinSan Luigi Hospital
  • Laura Cannella
    • Department of Cellular Biotechnology and HematologyUniversity La Sapienza
  • Caterina Stefanizzi
    • Department of Cellular Biotechnology and HematologyUniversity La Sapienza
  • Agostino Tafuri
    • Department of Cellular Biotechnology and HematologyUniversity La Sapienza
  • Angelo Fama
    • Department of Cellular Biotechnology and HematologyUniversity La Sapienza
  • Michelina Santopietro
    • Department of Cellular Biotechnology and HematologyUniversity La Sapienza
  • Giuseppe Saglio
    • Department of Clinical and Biological Sciences of the University of TurinSan Luigi Hospital
  • Giuliana Alimena
    • Department of Cellular Biotechnology and HematologyUniversity La Sapienza
Short Communication

DOI: 10.1007/s00280-008-0858-8

Cite this article as:
Breccia, M., Cilloni, D., Cannella, L. et al. Cancer Chemother Pharmacol (2009) 63: 1161. doi:10.1007/s00280-008-0858-8

Abstract

Imatinib is the treatment of choice for FIP1L1-PDGFRα (F/P+) positive myeloproliferative neoplasms, but little is known about optimal dose and duration of treatment to maintain complete molecular remission once achieved. We describe a case of F/P+ patients who started imatinib and reached a molecular remission, but did relapse after 15 months of therapy for poor adherence to therapy, and re-obtained remission only with standard dose of 400 mg/day. We reviewed the literature and highlights the need of quantitative molecular procedures to modulate imatinib dose.

Keywords

ImatinibHypereosinophilic syndromeFIPL1-PDGFR-alphaMolecular remission

Copyright information

© Springer-Verlag 2008